Back

Anticoagulation care in the electrophysiology lab: what do we know so far?

19 June 2017 (12:45 - 12:55)
Organised by:
Congress Presentation Part of: RE-CIRCUIT: uninterrupted dabigatran as a new strategy in atrial fibrillation ablation Atrial fibrillation (AF) EHRA Premium Access EHRA EUROPACE - CARDIOSTIM 2017

About the speaker

Photo
Professor Gregory Yh Lip

University of Liverpool, Liverpool (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
New evidence on periprocedural strategies for atrial fibrillation ablation: the RE-CIRCUIT trial.
Professor S. Willems (Hamburg, DE)
Presentation thumbnail
RE-CIRCUIT and reversal: how will our practice change?
Doctor H. Calkins (Baltimore, US)
Presentation thumbnail
Audience Q&A.
Professor G. Lip (Liverpool, GB)

Access the full session

Session thumbnail
RE-CIRCUIT: uninterrupted dabigatran as a new strategy in atrial fibrillation ablation

The Event

Event poster

EHRA EUROPACE - CARDIOSTIM 2017

19 June 2017 12:45 CET
You may be interested in
thumbnail
Congress Session
Antithrombotic therapy for critically ill patients: focusing on anticoagulants
26 March 2023
thumbnail
Congress Presentation
Safety and efficacy of anticoagulation therapy post atrial fibrillation ablation
9 March 2024
thumbnail
Congress Presentation
Activated clotting time for anticoagulation management during left-atrial catheter ablation: an international survey of current strategies
12 April 2026
thumbnail
Congress Presentation
A new clinical decision support tool based on personalized evidence-based medicine improves outcomes of anticoagulation therapy in patients with atrial fibrillation: an analysis from the AF Registry
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources